Literature DB >> 12670337

Disparate expression of the PTEN gene: a novel finding in B-cell chronic lymphocytic leukaemia (B-CLL).

Nicolas Leupin1, Bruno Cenni, Urban Novak, Barbary Hügli, Hans U Graber, Andreas Tobler, Martin F Fey.   

Abstract

One fifth of B-cell chronic lymphocytic leukaemia (B-CLL) patients exhibit loss of heterozygosity (LOH) at 10q23.3, the site of the tumour suppressor PTEN. Microsatellite markers mapped complete LOH to 10q23.3 in 2/41 B-CLL (5%) and allelic imbalances in 6/41 (15%). No PTEN gene mutations were found. PTEN protein expression was not detected in 11 B-CLL (28%), and was reduced in eight patients (20%). LOH or allelic imbalances at 10q23.3 were fairly frequent in B-CLL, but did not encompass the PTEN gene. Nevertheless, PTEN protein may be absent in B-CLL with a normal PTEN genotype, suggesting a role of this phosphatase in the molecular pathology of B-CLL.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12670337     DOI: 10.1046/j.1365-2141.2003.04227.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  14 in total

Review 1.  Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.

Authors:  Kumudha Balakrishnan; Varsha Gandhi
Journal:  Expert Opin Investig Drugs       Date:  2012-03-09       Impact factor: 6.206

2.  Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells.

Authors:  Mercè de Frias; Daniel Iglesias-Serret; Ana M Cosialls; Llorenç Coll-Mulet; Antonio F Santidrián; Diana M González-Gironès; Esmeralda de la Banda; Gabriel Pons; Joan Gil
Journal:  Haematologica       Date:  2009-10-08       Impact factor: 9.941

Review 3.  The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.

Authors:  Rui D Mendes; Kirsten Canté-Barrett; Rob Pieters; Jules P P Meijerink
Journal:  Haematologica       Date:  2016-09       Impact factor: 9.941

4.  microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival.

Authors:  Simona Rossi; Masayoshi Shimizu; Elisa Barbarotto; Milena S Nicoloso; Federica Dimitri; Deepa Sampath; Muller Fabbri; Susan Lerner; Lynn L Barron; Laura Z Rassenti; Li Jiang; Lianchun Xiao; Jianhua Hu; Paola Secchiero; Giorgio Zauli; Stefano Volinia; Massimo Negrini; William Wierda; Thomas J Kipps; William Plunkett; Kevin R Coombes; Lynne V Abruzzo; Michael J Keating; George A Calin
Journal:  Blood       Date:  2010-04-14       Impact factor: 22.113

5.  Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy.

Authors:  Muhan Chen; Dawid G Nowak; Lloyd C Trotman
Journal:  Clin Cancer Res       Date:  2014-06-15       Impact factor: 12.531

Review 6.  Role of microRNAs on therapy resistance in Non-Hodgkin's lymphoma.

Authors:  Rong-Li Zheng; Yu-Jie Jiang; Xin Wang
Journal:  Int J Clin Exp Med       Date:  2014-11-15

7.  Circulating microRNA-192 as a diagnostic biomarker in human chronic lymphocytic leukemia.

Authors:  S Fathullahzadeh; H Mirzaei; M A Honardoost; A Sahebkar; M Salehi
Journal:  Cancer Gene Ther       Date:  2016-09-23       Impact factor: 5.987

8.  The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions.

Authors:  Samantha D Pauls; Sandrine T Lafarge; Ivan Landego; Tingting Zhang; Aaron J Marshall
Journal:  Front Immunol       Date:  2012-08-09       Impact factor: 7.561

9.  p110δ PI3 kinase pathway: emerging roles in cancer.

Authors:  Niki Tzenaki; Evangelia A Papakonstanti
Journal:  Front Oncol       Date:  2013-03-01       Impact factor: 6.244

10.  PTEN and rapamycin inhibiting the growth of K562 cells through regulating mTOR signaling pathway.

Authors:  Zhi Y Cheng; Xiao L Guo; Xiao Y Yang; Zhi Y Niu; Shi H Li; Su Y Wang; Hao Chen; Ling Pan
Journal:  J Exp Clin Cancer Res       Date:  2008-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.